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INTRODUCTION: Primary nasopharyngeal melanoma is an exceedingly rare pathology with unclear etiol-
ogy and oftentimes obscure clinical presentation. Despite improved diagnostic capabilities, these lesions
are often diagnosed at an advanced stage and associated prognosis is poor, partly due to high rates of
recurrences and metastasis.
PRESENTATION OF CASE: A 74-year-old woman was diagnosed with metastatic melanoma to the liver, of
unknownprimary. Just prior to the time of diagnosis, she experienced several episodes of severe epistaxis
which she managed conservatively. Her symptoms eventually subsided without further medical evalu-
ation. The patient was initially treated with interleukin-2 (IL-2) for her advanced disease, but her cancer
progressed. She was then enrolled in a protocol for percutaneous hepatic perfusion (PHP) with mel-
phalan and had complete radiographic resolution of disease, yet her nosebleeds recurred and persisted
despite conservative measures. Six years after her initial diagnosis, a nasopharyngoscopy demonstrated
a pigmented lesion in the posterior nasopharynx. Surgical resection was performed (pathology consis-
tent with mucosal melanoma) followed by radiation therapy. She has since had complete resolution of
bleeding and shows no evidence of cancer.
DISCUSSION:Toour knowledge, this is theﬁrst report of a diagnosis of primarynasopharyngealmelanoma
6-years following complete remission of metastatic disease. Surgery remains the primary treatment for
disease and symptom control in this setting.
CONCLUSION: Timely diagnosis of nasopharyngeal melanomas remains challenging. Thorough clinical
evaluations shouldbeperformed in suchpatients, andattention shouldbepaid to recurrent andpersistent
symptoms, such as epistaxis and hearing loss. This may allow for earlier detection of primary disease.
Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Whereas cutaneous melanoma is a familiar entity to many clini-
cians andpatients alike, primary head andneckmucosalmelanoma
(HNMM) is a rare pathology with an unclear etiology and often-
times obscure clinical presentation [1,2]. Similar to cutaneous
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melanoma, there has been an increase in the incidence of HNMM
in the United States since the late 1980s, most notably in white
females ages 55–84 [3,4]. Despite advances in diagnostic capabil-
ities and treatment approaches, prognosis remains poor and the
5-year overall survival rate is 10–30%, partly due to high rates of
recurrences and metastasis [4].
Nasopharyngeal melanoma is an exceedingly rare type of
HNMM and its incidence is usually reported with nasal cavity and
sinonasal tract melanomas. Mucosal melanomas in these locations
account for 4% of HNMMs and 4% of nasal tract/nasopharyngeal
neoplasms [5].Hearing loss, epistaxis, andnasal congestion arepre-
senting symptoms, however the diagnosis is often delayed several
months following symptom onset [6,7]. We present a report of a
woman who had a complete response to systemic treatment of
http://dx.doi.org/10.1016/j.ijscr.2015.03.053
2210-2612/Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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metastatic melanoma of unknown origin. Six years later, a diag-
nosis of primary nasopharyngeal melanoma was made after an
extensive work-up for recurrent symptoms of severe right-sided
epistaxis andhearing loss.Herein,wedescribe the clinical decision-
making and multidisciplinary management involved in the care of
the patient.
2. Presentation of case
In February 2007, a 74-year-old woman presented with abdom-
inal pain and generalized malaise. A CT showed multiple liver
masses and subsequent biopsy was consistent with metastatic
melanoma. Extensive work-up did not reveal a primary source of
melanoma. Just prior to the time of diagnosis, she experienced
severe epistaxis that she treated conservatively; these symptoms
resolved and she did not pursue further medical work-up for
her nosebleeds. She was initially treated with interleukin-2 (IL-
2) for stage IV disease, but her cancer progressed. In November
2007, she enrolled in a National Institutes of Health (NIH) study
investigating percutaneous hepatic perfusion (PHP) with melpha-
lan for ocular or cutaneous melanoma metastatic to the liver.
She tolerated two doses, but stopped therapy because of sys-
temic toxicity. Despite no further treatment, her burden of disease
decreased at subsequent visits and she was declared to have
complete radiographic eradication of all tumor sites by April
2009.
In January 2013, the patient presented to an otolaryngology
clinic for follow-up of chronic right-sided cerumen impaction and
recurrent severe right-sided epistaxis. Following an unremarkable
clinical exam, she was continued on a moisturization regimen
with saline nasal spray, gel, and a humidiﬁer. Symptoms per-
sisted and the aforementioned regimen was modiﬁed to include
other over-the-counter agents. She was later evaluated in April
2013 with similar complaints as well as diminished hearing. On
exam, her physician noted right nasal turbinate swelling and
Fig. 1. Endoscopic evaluation revealed a dark melanotic lesion located in the right
nasopharynx (bottom left).
Fig. 2. Computed-tomography demonstrating a 1.3×1 cm lesion in the right
fossa of Rosenmuller involving the eustachian oriﬁce and tympanomastoid
effusion.
septal ooze, as well as right ear cerumen impaction. Nasal packing
was performed and the patient returned home, but bleeding per-
sisted. Thepatient soughtmedical evaluationat a local hospital, and
a limited nasal endoscopy was performed, revealing no bleeding
source and a widely patent nasal cavity with no suspicious lesions.
She subsequently returned toher original otolaryngology clinic and
a more complete nasopharyngoscopy was performed, revealing a
dark-nodular pigmented lesion in the right posterior nasopharynx
with no evidence of satellite melanosis (Fig. 1). Imaging showed
a 1.3×1 cm lesion in the right fossa of Rosenmuller obstructing
the eustachian oriﬁce and a right tympanomastoid effusion (Fig. 2).
Staging PET scan demonstratedmetabolic hyperactivity in this area
extending into the ipsilateral torus tubarius and posteriorly into
the eustachian tube oriﬁce but without further evidence of local
or metastatic disease. She underwent partial nasopharyngectomy,
posterior septectomy, and resection of right torus in June 2013 via
an endoscopic endonasal approach. Final pathology report demon-
strated malignant mucosal melanoma (positive for S-100, HMB45,
and Melan-A; BRAF and c-kit mutation-negative) and adjuvant
radiation therapy (total of 70Gy) was administered in September.
She has since been doing remarkably well. In October 2013, several
months following her surgery, examination of her right ear demon-
strated a clear external auditory canal,with no evidence of effusion,
retraction, or perforation. Surveillance imaging, clinical exams, and
laboratory studies through November 2014 have been unremark-
able for recurrent or metastatic disease, and she has had no further
episodes of epistaxis.
3. Discussion
Primary mucosal melanoma accounts for approximately 0.03%
of all cancer diagnoses, and head and neck cases account for
0.7–3.8% of melanomas [2,8]. Given its rarity, much of the man-
agement approach to nasopharyngeal melanoma is derived from
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experience with sinonasal tract melanomas. One clinicopathologic
review of nasopharyngeal/sinonasal tract melanomas performed
at a single center over 25 years included 115 cases, of which,
9 (7.8%) were nasopharyngeal in origin [5]. The most com-
mon symptoms reported, in decreasing order, were epistaxis,
mass/obstructive symptoms, difﬁculty breathing, pain, polyps,
and nasal discharge [5]. Timely diagnosis of nasopharyngeal
melanomas remains challenging, as such symptomsareoften indis-
tinguishable from benign processes and visual inspection is not
possible without endoscopy (unlike cutaneous melanoma) [5].
Hence, it is not surprising that several studies have observed a 6–8
month delay in diagnosis from the reported onset of symptoms
[5,6].
Surgical resection is theprimary treatmentmodality forHNMMs
and adjuvant radiation therapy improves local control, yet the
overall survival is poor independent of treatment approach [2,4].
Complete surgical excision to negative margins is the goal but is
not always possible, often a result of complex anatomy and prox-
imity of the tumor to vital structures [5,9]. For sinonasal malignant
melanomas, outcomes are similarwhen comparing endoscopic and
open surgical approaches [10]. In addition to surgery, radiation
and chemotherapy have been evaluated as adjuvant treatment
for HNMM; however, it is uncertain if either of these systemic
therapies improve survival outcomes [11,12]. Radiation therapy
following surgery offers better local-regional control than radiation
alone, and improves disease control even for small tumors [13].
The recurrence rate following deﬁnitive treatment for HNMM
approaches 50%, with a mean time interval to recurrence of 13–14
months [6,14]. An analysis from the Surveillance, Epidemiology,
and End Results (SEER) registry between 1973 and 2007 identi-
ﬁed several independent predictors of poor overall and disease free
survival [15]. Such factors include nasopharynx/paranasal sinus
location, age greater than 70 years and distant metastasis, all of
which are features pertinent to our case report [15]. At the molecu-
lar level, cell cycle and apoptotic regulatorsmay serve as prognostic
indicators in HNMMs, as expression of bcl-2 has been associated
with improved survival and loss of p16 with tumor progression
[16].
For certain pathologies, it is often difﬁcult to distinguish a
metastasis from a primary neoplasm, however, a de novo pri-
mary nasopharyngeal mucosal melanoma is much more likely
than metastasis [17]. Up to 50% of patients with primary HNMM
may develop distant metastasis to the brain, liver, and lungs
[18]. Metastatic melanoma has a poor prognosis, with an associ-
ated median survival of approximately 3–6 months [7,19]. Female
sex and prior immunotherapy have been associated with pro-
longed survival in patients with metastatic disease [19]. Cisplatin
and accelerated hyperfractionated radiation has been studied in
patients presenting with malignant melanoma of the nasal cavity
and nasopharynx that are too advanced for surgery [11]. Of four
such patients, three achieved complete local eradication of dis-
ease but later died of disseminated disease after 9–21 months, and
one patient had no evidence of disease at a 34-month follow-up
from treatment [11]. Our patient presented ﬁrst with metastatic
disease after progressing on IL-2 therapy and was enrolled on a
PHP protocol for ocular/cutaneous melanoma based on assump-
tion that this was likely of cutaneous origin. A study reviewing
PHP for unresectable hepatic malignancies demonstrated a 50%
overall response rate in patients with ocular melanoma, including
two complete responses with durations of 10 and 12 months [20].
The patient presented in this report has survived more than seven
years since her initial diagnosis, and to our knowledge, this is the
ﬁrst report of such a presentation and management of unknown
primary melanoma following successful treatment of metastatic
disease.
4. Conclusion
Nasopharyngeal mucosal melanoma is an exceedingly rare
tumor and there is a paucity of data regarding clinical presentation
and management of local and systemic disease. Surgery is the pri-
mary treatment and radiation therapy improves local control in
the adjuvant setting. This report demonstrates that resection of
a primary nasopharyngeal melanoma may be performed success-
fully after a delayed diagnosis following treatment and remission
of metastatic disease. Thorough clinical evaluations should be per-
formed in such patients, and attention should be paid to recurrent
and persistent symptoms, as epistaxis and hearing loss. This may
allow for earlier detection of primary disease.
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